Figure 3: Blood glucose levels over the time course
A display of the patient‘s highest (red) and lowest (blue) blood glucose levels for each day of her hospital stay, along with the concurrent Octreotide (grey) and glucose therapy (orange). Octreotide was paused on day 17 because of a DOTA-TATE-PET/CT-scan on day 18. The combination of 800 μg Octreotide per day and continuous intravenous glucose infusions maintained adequate blood glucose levels above 50 mg/dl. However, blood glucose levels were highly variable. Immediately after redebulking surgery on day 23, they stabilized at appropriate levels.